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 Triple-negative breast cancer (TNBC) is still one of the most enigmatic breast cancer types and no firm, efficient therapy 
has been established yet. Regarding its molecular profile and lack of specific receptors, angiogenesis, as an inseparable 
part of tumor biology, was taken into consideration as one of the leading causes of tumor progression. Taking into account 
cancerous neovascularization stages and recent scientific researches, it appears probable to understand the process of 
tumor progression and separate several ways of inhibiting this crucial phenomenon determining neoplasm invasiveness. 
Combination of traditional therapy and new antiangiogenic agents is a chance for patients to receive treatment as effective 
as patients with other types of breast cancer or cancer at all. New therapeutic methods may impact the genome level of 
carcinogenesis. There are many studies aimed at blocking transformed protooncogenes or restore the activity of tumor 
suppressor genes. Dealing with the process of cancer cells hypoxia and understanding the role of hypoxia inducible factor 
(HIF) and vascular endothelial growth factor (VEGF) – main angiogenesis inducers – let us introduce proper drugs blocking 
their activity (e.g. indenopyrazole 21, bevacizumab). Monoclonal antibodies, genetic therapies and newly synthesized drugs 
replace previously used therapeutic methods as poly (ADP-ribose) polymerase (PARP) inhibitors, mTOR kinase inhibitors, 
or Ras inhibitors. These new treatment methods include sunitinib, Aurora A kinase/tyrosine kinase inhibitor ENMD-2076, 
tested due to their multi-target actions, oncolytic viral therapy or small interfering RNA (siRNA). Despite numerous scien-
tific and clinical studies, triple-negative breast cancer remains difficult to treat and is characterized by significantly worse 
prognosis, statistically shorter five-year survival rate and tendency to relapse.
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Triple-negative breast cancer characteristics
Detection rate improvement, inventing and developing new 
ways of treatment and increasing accessibility belong to the gre-
atest challenges in modern oncology. According to the National 
Cancer Registry data, breast cancer is most frequent in Polish 
women population. The same data come from the USA, Canada 
and Western Europe, where breast cancer comprises about 22% 
of female cancers. Most common medical treatment strategies 
often include making use of presence on the cancer cell surface 
particular receptors. These are estrogen (ER), progesterone (PR) 
and human epidermal growth factor type 2 receptors (HER2) 
(Fig. 1). Lack of these receptors expression is a leading cause of 
receptor-negative cancers resistance to traditional therapies. 
Thus considering triple-negative breast cancer (TNBC), it is im-
possible to apply hormone or HER2 aimed therapies. This implies 
the necessity to introduce other therapeutic procedures, which 
may improve TNBC patients’ prognosis, what seems to be the 
most important challenge in TNBC treatment. 
19
TNBC is diagnosed in 12–17% of all breast cancer cases. 
The risk of this phenotype increases before age of 50 and is 
connected with BRCA1 mutation more than any other type 
of breast cancer. As the TNBC cells are frequently relatively 
heterogeneous and low-differentiated, this cancer type is con-
sidered to have an aggressive course, be extremely resistant 
to chemotherapy, as well as eager to develop some distant 
metastases and cause short life expectancy thus resulting in 
extremely poor prognosis [1] (Fig. 2).
The TNBC term is sometimes equated to basal-like breast 
cancer. This is , though, only partially true, for all oncologists 
must be aware of distinguishing six subtypes of TNBC: basal-like 
1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchy-
mal (M), mesenchymal stem-like (MSL) and luminal androgen 
receptor (LAR). However, BL1 is in great majority the kind of 
basal-like breast cancer sensu stricto (81%), the rest have its 
features only in about half of all cases or do not have them at 
all. In general, 50 to 80% of TNBCs are also a basal-like breast 
cancer [2–4].
Basal-like type is characterized not only by lack of ER, PR 
and HER2 expression, but also a number of features specific 
for basal cells. These are expressions of: cytokeratin 5, 6, 14, 
17, laminin, p53, P-cadherin, common acute lymphoblastic 
leukemia antigen (CALLA) or smooth muscle actin (SMA), as 
well as epidermal growth factor receptor (EGFR/HER1) [3, 5–7]. 
High level of Ki-67 has been recently added to this list as an 
indicator of high mitotic index and unfavorable prognosis [5].
LAR is the only type of TNBC which could be treated with 
hormone therapy by using androgen receptor antagonists. 
Although constituting only about 11% of TNBCs [3], it cannot 
be regarded as a proper solution for all patients presented 
with this type of cancer. It is the other cause forcing scientists 
to develop non-standard ways of treatment, to which TNBC 
patients may respond. If we omitted obvious cytostatic therapy 
and poorly working chemotherapy, there are some therapies 
under investigation, i.e.: mTOR kinase and PARP1/PARP2 inhi-
bitors or epidermal growth factor receptor (EGFR) and vascular 
endothelial growth factor (VEGF) inhibitors.
Chemotherapeutic agents used in TNBC therapy
PARP1 and PARP2 inhibitors (poly (ADP-ribose) polymerase 
1 and 2 inhibitors) influence the functioning of poly (ADP-ri-
bose) polymerase and corrupt single-strand damages repair, 
increasing pace of damages accumulation and as an effect 
double-strand impairments are very likely to come forth. 
A very frequent BRCA1 mutation in TNBC patients is worth 
noticing. This gene is responsible for maintaining double-
-strand integrality. Its mutation and high mitotic index cause 
inappropriate functioning of the cell repair mechanisms. Using 
PARP1 and PARP2 inhibitors may be the cause of cancer cells 
apoptosis despite their defensive strategies. Iniparib, olaparib 
and veliparib are used as PARP inhibitors and each of them 
is currently in stage II of clinical studies as a BL1, BL2 and IM 
type remedy [8–10]. 
Mammalian target of rapamycin (mTOR) is a serine threoni-
ne kinase which is considered as an intersection of numerous 
cell metabolic pathways – including growth, survival, and 
programmed cell death. As its name suggests, rapamycin is 
a substance, which inhibits the activity of mTOR and rapamy-
cin’s derivative – everolimus – is used together with cytostatics 
in M, MLS and LAR types to prevent distant metastases and 
to improve the patients’ overall prognosis. Despite the low 
frequency of mTOR/PI3K/AKT signal track genes mutation in 
TNBC compared to all types of breast cancer, this therapy still 
significantly increases the response to the treatment also in 
TNBC patients [3, 11].
However, EGFR inhibitors seem to have higher effective-
ness in HER2 positive cancers treatment, one of them – gefi-
nitib is also used concerning TNBC, causing cancer cell cycle 
arrest in approximately 50% of all cases. The regular treatment 
includes involving carboplatin and docetaxel together with 
gefinitib to achieve synergistic reaction [12].
Figure 1 . Example of immunohistochemical HER2 staining of triple-
negative breast cancer (metaplastic breast cancer), scored 0 (stained 
cells accounted for less than 10% of total tumor cells); the micrograph 
was taken with 20x lens
Figure 2 . Histopathological image of metaplastic breast cancer assessed 
as triple-negative breast cancer. Visible necrosis and blood vessels 
formation, histological grade 3 (G3); original magnification 20x
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Formation of new blood vessels – angiogenesis 
and neovascularization
The inevitable part of cancer invasiveness and progression is to 
strive for maintaining the proper level of cancer cells nourish-
ment. This cannot be achieved without modifying peritumoral 
vascular environment. The tumor high metabolic rate and 
constantly increasing cell amount elevate cancerous oxygen 
and nutrients requirements. Hence the tumors excrete many 
of proangiogenic and neoangiogenic factors, which promote 
new vessels formation or bifurcation of already existing ones. 
This provides a perfect opportunity for invasive, non-adherent 
cells, to spread into and settle in other organs creating distant 
metastases.
New blood vessels can be formed in two different ways. 
The first one is called vasculogenesis and represents develo-
ping primitive network of blood vessels from precursor cells 
named hemangioblasts. These “vascular seeds” are dissemina-
ted from blood islands located in yolk sack at the early stages 
of embryo development. Afterwards the angiogenesis follows, 
which is much more dynamic process, depending on the body 
state and controlled by specific substances produced by nu-
merous cells – cancerous or intact ones. It consists in forming 
new vessels from the endothelium of already existing ones 
and it is much more frequent phenomenon than vasculoge-
nesis [13]. Angiogenesis is considered as a real breakthrough 
in tumor progression process. Until the moment when the 
necessary sources of oxygen and nutrients are provided, even 
the most malignant cancer is strictly confined and the relative 
equilibrium concerning cancer cells mitosis and deaths is main-
tained [14]. As soon as the proangiogenic factors are activated 
and antiangiogenic are inhibited, a cell or cell group becomes 
phenotypically proangiogenic, what will be described later on.
Neovascularization or neoangiogenesis is a term thatre-
fers only to pathological vessels growth, i.e. during tumor 
development and is described as forming new capillaries in 
the cancer parenchyma or surrounding, what classifies it as 
an option of angiogenesis [15]. Neoangiogenesis refers to this 
phenomenon in neoplasm, since angiogenesis is responsible 
for the formation of blood vessels in healthy tissue. However, 
the prefix “neo-” was quite evocative suggesting “new” (gr. 
νεο-: neo-, from νέος: néos - “new, young”) and pathological 
(“neoplasm”) matter, it has not fully superseded previous term 
and coexists worldwide with “angiogenesis” in reference to 
cancer vessels growth. 
Angiogenesis is a complex process, which is crucial for 
tumor progression. Each of its stages, including endothelial 
cells activation, endothelium fenestration, intracellular matrix 
degradation, migration of activated cells and finally forming 
brand new vessels, one by one require constant stimulation 
by proangiogenic agents, primarily VEGF, and inhibition of 
antiangiogenic substances, thrombospondin 1 (TSP-1) above 
all. Cancer cells mass would be definitely too small to produce 
such quantities of VEGF as well as RAS mutation, which cause 
impaired transcription of TSP-1 gene and is frequently present 
in cancer cells, is not enough to significantly influence the 
amount of TSP in the tumor surrounding [16].
“Angiogenic field” conception
Angiogenic field conception was firstly described by Kalas et al. 
(2005) [17]. It assumes that, together with decreased amount of 
TSP, cancer cells produce and excrete substances, which lower 
the expression of TSP-1 gene in non-transformed ambient cells 
and cause balance shift to the presence of angiogenic actions. 
Such formation is also called “heterogeneous angiogenic unit”. 
Angiogenic fields cannot be mistaken for hot spots, frequen-
tly appearing in the literature [18, 19]. Hot spots are specific 
tumor areas, where the density of neovascularizated vessels is 
much higher. What is more, hot spots presence is connected 
with poor prognosis and worse response to the chemo- and 
radiotherapy [20, 21]. There is currently no scientific evidence 
if angiogenic fields and hot spots of angiogenesis share the 
same location during different cancer progression stages.
As the study by Kalas et al. (2005) has revealed, cancer cells 
do not have to affect angiogenesis process directly. TSP-1 gene 
decreased expression level in healthy cells can be also modified 
by presence of thrombocytes and facilitators of inflammation, 
which are frequently present around the tumor cells [22–24]. 
This phenomenon perfectly presents angiogenic fields influ-
ence on coagulation system.
Angiogenic phenotype and tumor suppressor 
genes
Angiogenesis had been considered as a process, which is 
secondary to the cancerous transformation. Tumor suppressor 
genes mutations or loss of heterozygosity (LOH) in specific 
diseases (i.e. Li-Fraumeni syndrome [25, 26]) had not been 
connected with proangiogenic processes, but only with ma-
lignant changes in cells. It was the cancerous tissue growth 
and its abnormal pace, which was thought to be responsible 
for switching to proangiogenic phenotype and angiogenesis 
itself. Further research found that, however, the previous idea 
was correct and hypoxia does play an enormous role in an-
giogenesis, cancer cells also have another way to induce this 
process crucial for their growth. An in vitro fibroblasts culture 
was organized and they were taken from patient who suffered 
from Li-Fraumeni syndrome. It transpired that the proangio-
genic phenotype, presented as a significant decrease of TSP-1 
gene expression, appeared immediately after performing LOH 
and together with cancerous transformation, despite proper 
oxygenation conditions [27]. 
Oncogenes as neoplasm’s vascular processes 
modifiers
Angiogenesis regulation from oncogenes concerns primarily 
Ras/VEGF relations. Over 20 years ago it become clear, that Ras 
gene mutation not only leads cells to the cancerous transfor-
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mation, but also induces proangiogenic phenotype [28]. In 
vitro culture of human intestine epithelium cells with faulted 
Ras gene began to present proangiogenic features – stimu-
lating endothelial cells growth and their migration. They also 
started becoming cancerogenic after in vivo implantation. That 
peculiar feature was absent immediately after VEGF blocking 
antibodies usage, what confirmed, that Ras gene influences 
the signal pathway of VEGF production and release. Another 
oncogenes acting as vascular processes modifiers are: HER2, 
EGFR, PTTG1 and HPV-16 which stimulate VEGF production. 
C-myc and Py MT inhibit TSP. Mutated V-Src gene is capable of 
acting both aforementioned ways (Fig. 1) [16, 29].
Tumor cell hypoxia induces angiogenesis
A phenomenon of hypoxia is the most important factor indu-
cing vascularization process lifelong. We must not consider hy-
poxia as an unequivocally negative process. There are number 
of conditions, when it is positive, even desirable act – e.g. extra 
capillarization in skeletal muscles as an effect of long-term 
exercises and repeated hypoxia periods or staying high above 
sea level, when adaptation to hypoxia includes some changes 
like capillarization or increasing erythropoietin synthesis and 
secretion [29, 30]. At the same time, the awareness of its po-
ssible devastating role is absolutely necessary. Anoxic cancer 
cells produce the same cytokines as healthy anoxic cells would 
in order to signal to the organism a burning need of more 
oxygen. This kind of “cells cry for help” is hypoxia-inducible 
factor (HIF) – the most important but not the only one VEGF 
activator [31]. HIF is a transcription factor consisting of two he-
terodomains, α and β, which are detected in couple of isoforms, 
e.g. HIF-1β is constantly present in human cells nucleus, HIF-1α 
and HIF-2α are the proper proangiogenic agents and HIF-3α is 
even a particle inhibiting VEGF expression. VEGF expression is 
elevated because of HIF joining its gene promoter, as well as eli-
mination half-life of VEGF mRNA is lengthened due to binding 
specific proteins to their 3’ end [32, 33]. Fledgling vessels are 
frequently underdeveloped and subnormal, additionally the 
tumor growth constantly occurs, what leads to deepen hypoxia 
and the vicious cycle is completed (Fig. 3). HIF neutralization 
is based on two processes. The first one is oxygen caused HIF 
hydroxylation and later joining with vHL protein and ubiquiti-
nation. Situation of impaired HIF-hydroxylase enzyme or vHL 
is identical to hypoxia, considering angiogenesis promotion. 
VEGF family consists of VEGF-A, PGF (placental growth 
factor), VEGF-B, VEGF-C, VEGF-D and VEGF-E. Among them, 
VEGF-A plays the most significant role. It influences VEGF re-
ceptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2), located only 
on the surface of endothelial cells and the signal is afterwards 
conducted through tyrosine kinase cascade. VEGF-C and -D 
affect endothelium of lymphatic vessels through VEGF receptor 
3 (VEGFR3). Vascular endothelial growth factor not only induces 
cells mitoses and proliferation, but also enables blood serum 
HIF – hypoxia inducible factor; PTTG1 – pituitary tumor-transforming gene 1 (securin); TGF – tumor growth factor; TNF – tumor necrosis factor; HGF – hepatocyte growth factor 
(scatter factor); KGF – keratinocyte growth factor; IGF – insulin-like growth factor; VEGF – vascular endothelial growth factor;  TSP – thrombospondin; Py MT – polyoma middle 
tumor gene; EGFR – epithelial growth factor receptor; PGE – prostaglandin E; IL – interleukin
Cancer cells hypoxia 




c-myc, Py MT, v-src mutations 
Hypoxia-induced transcription 
factors (HIF-1α, HIF-2α) 
VEGF  gene increased 
transcription 
ras, HER2, EGFR, PTTG1, v-src 
mutations TGF-α, TGF-β, PGE1, 
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VEGF mRNA stabilization 
Figure 3 . Vicious circle of hypoxia-induced neovascularization and other proangiogenic factors influence
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or plasma to extravasate by effectively (50 000 times more) 
eliciting endothelial pores formation. It allows fibrinogen to 
transform into fibrin and provides comfortable conditions for 
cancer cells to organize their new basis, what pays dividends 
not only in creating suitable stroma, but also separating cancer 
mass from immunocompetent cells present in or approaching 
the tumor location. This makes VEGF overexpression serious 
immunosuppressive factor in pathogenesis of such neoplasms 
as: breast and stomach cancer, non-Hodgkin lymphomas or 
small-cell lung carcinoma [13, 34]. Recent researches also re-
veal that the level of VEGF expression is significantly higher in 
TNBC than in any other type of breast cancer and may be even 
a grading factor in differentiation of TNBC from non-TNBC. This 
border has been set at the level of 665 pg/ml with expected 
sensitivity and specificity of 88.9% and 99.3% [35].
Angiogenesis and its inhibitors
Each of aforementioned angiogenesis inducers can be inhi-
bited by proper treatment. The main task of contemporary 
clinical oncology is to improve results of using medications 
by defining targeted, associated therapies for all neoplasm 
subtypes. The process of angiogenesis, which is inevitable in 
all invasive forms, should be considered as one of the most 
important research directions. Angiogenesis inhibitors can be 
divided in two groups. 
The first one consists of endogenous inhibitors. Their de-
activation, inhibition or lack of expression, is a crucial require-
ment for cancer to maintain neovascularization, oxygenation 
and nourishment at the proper level. Among endogenous 
angiogenesis inhibitors we can distinguish TSP, aforementio-
ned endothelium cells mitosis and differentiation inhibitor, 
angiostatin, protein constituting from plasminogen after its 
lysis, immunological cytokines, e.g. interferons and interleukins. 
What is extremely important for tumor mass, it is an uninter-
rupted contact with any kind of basis. Stroma remodeling 
requires specific enzymes, which allow digesting ingredients of 
extracellular matrix (ECM) (e.g. collagen type IV) and obviously 
inhibiting them is the way to stymie cancer cells. These factors 
are four members of tissue inhibitors of metalloproteinase 
family (TIMP 1, 2, 3 and 4) [36, 37]. There is also vascular endo-
thelial growth inhibitor (VEGI), endothelium cells apoptosis 
regulator, which induces cell suicide most likely via death 
receptor-3 (DR3). However, the role of VEGI is proven in small 
number of cases, still hardly known and requires much more 
studies [38]. Selected endogenous inhibitors are presented in 
Table I. This group assumes using as a medicine compounds 
present constantly in human body, but in insufficiency due 
to disease process. That is a reason why many researches are 
concentrated around TIMP family (identical actions provides 
batimastat and marimastat, which unfortunately performed 
poorly during clinical tests [39]) and TSP (TSP mimicking pep-
tides: ABT-510 and ABT-898 [40]).
Another way, probably more popular and frequently used, 
is laboratory synthesis of substances which are able to block 
VEGF-dependent angiogenesis and it is concerning each level 
of VEGF overexpression or action. Among these antiangiogenic 
substances the monoclonal antibodies against VEGF definitely 
dominate. Bevacizumab is a recombinant humanized mo-
noclonal antibody, which was the first commercially available 
angiogenesis inhibitor. It coats VEGF-A particles and forms an 
inactive complex, which is easily metabolized and eliminated. 
Soluble receptors for VEGF are also in use. SFlt-1 and sFlk-1 bind 
to VEGF, competing thereby with VEGF receptors on the surface 
of endothelial cells, decreasing direct proangiogenic influence. 
On the other hand, there are specific substances, which act just 
the opposite way – their conformation considering binding 
VEGF-VEGFR site is similar to VEGF particle, what allows it to 
match with superficial receptors and compete with VEGF, 
causing the effect as above-mentioned soluble receptors in 
another way – not reducing active VEGF concentration, but 
saturating its receptors [37].
Answering the question about VEGF inducing agents 
expression and increasing angiogenesis indirectly is also an 
answer to the question about present and potential therapies 
targets. Exemplary drug aim can be HIF – the most common 
proangiogenic mediator, signaling hypoxia. Ganetespib in-
duces degradation of all particles protected by chaperone 
proteins HSP90, what includes HIF-1α (but not HIF-2α) and 
significantly lowers the VEGF level [41]. Another discovered po-
tential therapeutic course considers using 2-methoxyestradiol 
Table I . Endogenous angiogenesis inhibitors
Endogenous angiogenesis inhibitor Source
Vascular endothelial growth inhibitor (VEGI) Endothelium cells
Thromospondin-1 (TSP-1) Platelets, immature astrocytes during brain development
Platelet factor 4 (PF4) = chemokine (C-X-C motif ) ligand 4 (CXCL4) Platelets
Interleukin 12 (IL-12) Dendritic cells, macrophages, B-lymphoblastoid cells
Angiostatin Autoproteolytic or enzyme-induced cleavage of plasminogen
Angiopoietin 2 Sites of vascular remodeling
Interferon α (IFN-α) Monocytes, macrophages, “null” cells
Interferon β (IFN-β) Fibro blasts
Interferon γ (IFN-γ) T-cells, natural killer cells, natural killer T-cells
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(2ME2), a compound responsible for interphasic microtubules 
disruption. After positive clinical trials, this drug may become 
one of the most effective, because it does not only destabilize 
cell cytoarchitecture and prevent from exponential tumor 
growth, but also, as the researchers have found, as a result – it 
downregulates HIF expression and inhibits angiogenesis. These 
findings not only have shown a new way of cancer treatment, 
but also demonstrated relations between those two pheno-
mena [42]. Recent studies revealed that Ras pathway inhibition 
may be an efficient way to deal with angiogenesis as well. 
Research on mice have proven that application of exogenous 
α-miR-132 prevents angiogenic sprouting and as a result ocular 
neovascularization better than any previous VEGF inhibitor [43]. 
Further tests are necessary in order to check if such therapy 
has any hope of success in cancer models. 
Proangiogenic switch is well known, but there are also 
some findings available, indicating that this occurrence may 
be reversible. Using established human liposarcoma xeno-
graft model, Rogers et al. (2014) revealed that a certain, small 
number of neoplasm cells coming from one stem cell, after a 
couple of in vivo cycles, formed microscopic, dormant tumors. 
These studies have shown that angiogenic phenotype is mal-
leable and can be reverted – spontaneously or inducibly, what 
unquestionably deserves further attention [44].
We must not forget about undesirable or adverse effects 
of antiangiogenic therapy. There are many studies confirming 
shortening of overall survival time in process of VEGF inhibitors 
treatment. In spite of shrinking of primal tumor mass and inhi-
biting tumor progression due to its antiangiogenic actions, lack 
of oxygen and growing hypoxia induce epithelial-mesenchymal 
transition, process of losing polarity and adhesion factors by 
cancer epithelium cells. This leads to elevated cancerous cells 
intravasation and distant metastases are more eager to reveal – 
generalized neoplastic disease develops [45]. Another unwanted 
effect is possibly high risk of hypertension. McIntyre et al. (2014) 
presented a couple of VEGF inhibitors’ mechanisms leading to 
increased blood pressure. These are: decreasing of nitric oxide 
metabolites level and prostacyclin signaling, overexpression of 
endothelin or volume overload due to shortage of fenestration 
spots in endothelium [46]. VEGFR-aimed therapy can also indu-
ce diabetes development, as VEGFR plays a significant role in 
endothelium of islets of Langerhans maintaining [37].
Antiangiogenic therapy in TNBC – a new insight
Because of TNBC characteristics, except for L type, hormonal 
or HER2 aimed therapy is believed to be irrelevant in this type 
of cancer. Hence antiangiogenic drugs, which are considered 
as important adjuvant therapy in other cancers, in TNBC are 
often a real backbone of treatment process together with 
PARP inhibitors. Scientists dealing with TNBC are especially 
aware of neovascularization importance and they are those 
who frequently introduce brand new look on cancerous neo-
vascularization issue. 
In addition to all above-mentioned angiogenesis inhi-
bitors, there are a couple of new ideas for disturbing this 
process, developed in models of TNBC. One of them is Aurora 
and angiogenic kinase inhibitor ENMD-2076. This substance 
is responsible for arresting tumor cells in G2 phase, a moment 
of mitosis, when serine-threonine kinase Aurora, frequent 
anticancer therapy target, plays a crucial role and induces 
caspase-dependent apoptosis. Interestingly, treatment with 
ENMD-2076 provides better results in PR, ER and HER2 nega-
tive cells, what makes it a perfect solution in TNBC. Another 
advantage of this treatment type is the fact that p53 mutation, 
frequently present in TNBC, makes cancer cells even more 
sensitive for its effects. Additionally, ENMD-2076 is an inhibitor 
of angiogenic tyrosine kinases – especially VEGFR, disturbing 
proangiogenic signals transducing, what makes it multi-target 
drug and defines its efficiency [47].
The other studies investigated the influence of sunitinib 
on basal-like TNBC type. Chinchar et al. (2014) have proven 
that sunitinib significantly inhibits apoptosis resistance, mitoses, 
proliferation and invasion in cultured basal-like breast cancer 
cells, as well as lowers VEGF protein level. However, the sunitinib 
therapy must be supported by γ-secretase inhibitor, for sunitinib 
promotes growth of breast cancer stem cells (CSCs) through 
interfering with Notch protein expression and inducing hypoxia. 
This innovative combined therapy might simultaneously target 
neovascularization and inhibit breast CSCs mitoses [48]. Afore-
mentioned treatment including ganetespib blocking HIF-1 was 
also performed successfully on TNBC model [42].
Most recent studies constitute three major milestones in 
cancer therapy: cycle checkpoint inhibitors, siRNA encapsu-
lated in immunoliposomes and oncolytic virus therapy. All 
of them were tested on TNBC and last two promise new di-
rections in antiangiogenic therapy. siRNA (small interfering 
RNA) is a short, double stranded RNA particle, interfering with 
homologous mRNA and inhibiting transcription. Required 
precision in affecting only faulted cells and avoiding endo-
genous enzymes are nowadays ensured by encapsulating 
with liposomes – immunoneutral carriers. The drug infiltrates 
tumor mass thanks to enhanced permeability and retention 
effect and lipid integument is projected to destabilize with 
inner (decreased pH in tumor environment, elevated tem-
perature) or outer (radiation, ultrasound) factors [49]. Specific 
siRNA sections have already been tested in vitro (AML – target: 
CD33, HER2-positive breast cancer – target: HER2) and in vivo 
(neuroblastoma – target: disialogangloside GD2). As to TNBC, 
lipocalin 2 (Lcn2) has been shown to promote epithelial to 
mesenchymal switch and induce neovascularization process 
in cancer through VEGF concentration increase. Guo et al. 
(2016) revealed that intracellular adhesion molecule 1 (ICAM-1) 
– targeted Lcn2 siRNA-encapsulating liposomes inhibit neova-
scularization and may be useful in future clinical approach [50]. 
Natural or genetically engineered viruses infecting and bre-
aking down cancer cells become experimental oncologists’ con-
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cern bringing to life the idea of oncolytic virus therapy. Already 
in 1912 De Pace reported cervical cancer regression case after 
vaccination against rabies but only after over one hundred years in 
2015 first oncolytic virus drug was approved in Europe and USA – 
T-VEC (talimogene laherparepvec), modified herpes simplex virus 
type 1 introduced to therapy of advanced malignant melanoma, 
suppressing tumor expansion and expanding overall survival. 
Viruses in cancer treatment found their places also in hepatocel-
lular carcinoma (vaccinia virus), urinary bladder cancer (adenovirus 
CG0070) and head and neck cancers (one of reoviruses) [51]. New 
scientific impact resulted in Gholami et al. (2014) study. Modified 
vaccinia virus (GLV-1h164) turned out to decrease VEGF level, 
encoding single chained antibody against this proangiogenic 
agent. Together with determination of cytotoxicity at the level of 
90% within 4 days, GLV-1h164 and its potent successors appeared 
to be a remarkable direction in TNBC therapy [52].
Other pathways suspected to inhibit neovascularization are 
constantly under investigation and Liang et al. (2017) discovered 
that activation of G protein-coupled estrogen receptor (GPER) re-
duced IL-6 level limiting inflammation and VEGF level, corrupting 
cancerous vessels growth process [53]. Da Motta et al. (2017) de-
scribed the process of epigenetic affecting of tumor progression 
and hypoxia. One of bromodomain and extra-terminal inhibitors 
(BETi) – JQ1, doubly influences cancer growth. Not only does it 
decrease the amount of hypoxia-induced genes, i.e. VEGF, HIF, but 
also stops HIF from binding with effectors of neovascularization. 
Considering TNBC’s high aggressiveness, therapy resistance and 
usually poor outcome, presenting such a pleiotropic characteristic 
is undoubtedly desirable and promising [54]. 
The uniqueness of TNBC among other breast cancers was 
well demonstrated by Wang et al. (2018). Not only is TNBC 
resistant to common antiestrogen therapy due to lack of 
hormone receptors, but he also found malignant cells to be 
vulnerable to just the opposite – estrogen-based therapy. 
GPER-1 (G-protein-coupled estrogen receptor-1) expression 
was analyzed in the TNBC cell lines MDA-MB-468 and MDA-
-MB-436 to be activated by 17β-estradiol and inhibits VEGF 
expression disturbing neovascularization, tumor growth and 
metastatic processes. In vivo trials in mice revealed significantly 
lower microvascular density (MVD) and tumor size in indivi-
duals exposed to 17β-estradiol than in control group what 
constitutes estrogen-GPER-1 pathway to be a promising a new 
TNBC, and cancer in general, treatment method after further 
investigation and clinical trials [55].
Ribatti et al. (2016) performed a reliable summary of issues 
concerning angiogenesis phenomenon in TNBC putting em-
phasis on some specific aspects of the process and different 
ways of strangling it as well as an objective assessment of 
clinical outcomes. Presented review clarifies MVD as a signi-
ficant disease intensity indicator as well as clinical outcome 
prognostic factor that could be measured and used to com-
pare effectiveness of various therapies. The authors also try to 
identify precise source of elevated proangiogenic factors in the 
tumor environment and to present studies convincing them to 
be tryptase-positive mast cells, which incidence in tumor sam-
ples increases proportionally to angiogenesis severity – MVD 
and presence of micrometastases in sentinel lymph nodes. In 
spite of decades of auspicious in vitro studies, TNBC is still con-
nected with poor clinical outcome. However, the combination 
of conventional chemotherapy and antiangiogenic drugs has 
reached a moderate success and TNBC patients can actually 
benefit from it, further research is continuously required to 
fulfill great hopes placed in it. Ribatti et al. (2016) propose to 
search for more effective therapy in the current of personalized 
medicine. Targeted therapy achieved with thorough marker 
diagnostic should allow to project individual scheme for each 
patient and result in increased survival rate, still the costs of 
such intention are the most critical concern [56].
Summary
Process of angiogenesis in TNBC is crucial. The first reason is the 
same as considering other cancer types – neovascularization 
must be induced by transformed cells, in other option tumor 
growth will be limited and cancer will not reveal its potential. 
The other ground is connected with molecular profile of TNBC 
cells. Shortage of possible targets for therapy forces scientist 
and clinical oncologist to seek for solutions in angiogenesis 
inhibitors more often than in any other cancer type. The will 
of finding proper TNBC therapy is definitely the main driving 
force of antiangiogenic factors researches. Numerous new 
ideas come up every year, but the clinical results most often 
do not correspond with experimental ones, regarding the use 
of mice models or trials of inhibiting angiogenesis of human 
tumors inside animals’ body. However, the phenomenon of 
angiogenesis is still reasonably considered as one of the most 
important testing direction in TNBC therapy.
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